세계의 폐암 액체생검 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the global Lung Cancer Liquid Biopsy Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Lung Cancer Liquid Biopsy Market Size (2025E): US$ 824.7 Mn
• Projected Market Value (2032F): US$ 1,900.5 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 12.7%

Lung Cancer Liquid Biopsy Market - Report Scope:

The lung cancer liquid biopsy market focuses on non-invasive diagnostic methods that utilize blood and other body fluids to detect tumor biomarkers in lung cancer patients. These biopsies are revolutionizing cancer diagnostics and management by offering quicker turnaround times, reduced patient discomfort, and real-time monitoring of tumor progression or therapy response. With rising lung cancer incidence globally and increasing adoption of precision medicine, liquid biopsy is emerging as a powerful tool in oncology diagnostics. This market includes a wide range of products and services, including instruments, reagents, and bioinformatics solutions designed for early detection, genetic profiling, and therapeutic decision-making in both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC).

Market Growth Drivers:

The growth of the global lung cancer liquid biopsy market is being significantly driven by the rising global prevalence of lung cancer, coupled with a growing demand for minimally invasive diagnostic procedures. Technological advancements in molecular diagnostics, particularly in next-generation sequencing (NGS) and PCR-based techniques, are making liquid biopsy tests more accurate and accessible. Additionally, increasing focus on personalized medicine is pushing healthcare providers and oncologists to adopt liquid biopsies for real-time tumor profiling and monitoring. Supportive regulatory approvals and increasing healthcare spending, especially in developed nations, are further contributing to market expansion. The growing preference for early and precise cancer detection methods and the potential of liquid biopsies to overcome limitations of traditional tissue biopsies are also propelling market demand.

Market Restraints:

Despite the promising growth trajectory, the lung cancer liquid biopsy market faces several key challenges. High costs associated with advanced liquid biopsy technologies can restrict adoption, particularly in low- and middle-income countries. The sensitivity and specificity of some assays, especially in early-stage cancer detection, remain areas of concern, potentially leading to false positives or negatives. Limited awareness among patients and healthcare providers in certain regions further impedes market penetration. Additionally, stringent regulatory frameworks and reimbursement hurdles can delay product launches and limit accessibility, affecting overall market growth.

Market Opportunities:

The lung cancer liquid biopsy market presents considerable opportunities fueled by the expansion of research into new biomarkers, including extracellular vesicles and circulating tumor cells, which can enhance diagnostic accuracy. The ongoing development of multi-analyte liquid biopsy panels and integration of AI and machine learning in bioinformatics offer pathways to improved diagnostic precision and efficiency. Emerging economies, especially across Asia-Pacific and Latin America, represent untapped potential with growing cancer burden and expanding healthcare infrastructure. Furthermore, collaborations between diagnostic companies and pharmaceutical firms for companion diagnostics in targeted therapies are opening new growth avenues. Continued investment in R&D and clinical trials aimed at validating new biomarker combinations will likely drive innovation and market competitiveness.

Key Questions Answered in the Report:

• What are the primary factors driving the global lung cancer liquid biopsy market's growth?
• Which regions and market segments are experiencing the highest demand for lung cancer liquid biopsy diagnostics?
• How are advancements in genomics and personalized oncology influencing market dynamics?
• Who are the key players in the lung cancer liquid biopsy market, and what strategies are they adopting to stay competitive?
• What are the emerging trends and future projections for the global lung cancer liquid biopsy market?

Competitive Intelligence and Business Strategy:

Leading players in the global lung cancer liquid biopsy market, such as Bio-Rad Laboratories, Agilent Technologies, Thermo Fisher Scientific, Illumina, and F. Hoffmann-La Roche, are focusing on developing high-sensitivity diagnostic platforms and expanding their liquid biopsy portfolios. These companies are increasingly investing in strategic collaborations with research institutions and biotech firms to enhance their R&D capabilities. Mergers, acquisitions, and licensing agreements are common strategies aimed at boosting technological integration and expanding global reach. Key players are also emphasizing regulatory approvals and global certifications to gain market trust and improve reimbursement prospects. Efforts to combine multiple biomarkers into single-panel tests and the integration of cloud-based platforms for data interpretation are setting new standards in the field.

Companies Covered in This Report:

• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Oncocyte Corporation
• NeoGenomics Laboratories
• Lepu Medical Technology (Beijing) Co., Ltd
• QIAGEN
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd
• Sysmex Corporation
• BioView

Market Segmentation

By Product:

• Instruments
• Kits and Reagents
• Software and Services

By Technology:

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR, Microarrays)

By Biomarker:

• Cell-free DNA (cfDNA)
• Circulating Tumor DNA (ctDNA)
• Extracellular Vesicles (EVs)
• Circulating Tumor Cells (CTC)
• Others

By Indication:

• Small Cell Lung Cancer (SCLC)
• Non-Small Cell Lung Cancer (NSCLC)

By Sample:

• Blood
• Cerebrospinal Fluid (CSF)
• Plasma
• Serum
• Others

By End-user:

• Hospitals
• Reference Laboratories
• Academic & Research Centers
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Lung Cancer Liquid Biopsy Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Disease Epidemiology
• 3.3. Regulatory Landscape
• 3.4. List of Suppliers
• 3.5. Porter's Five Forces Analysis
• 3.6. PESTLE Analysis
• 3.7. Promotional Strategies, By Key Players

4. Global Lung Cancer Liquid Biopsy Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Lung Cancer Liquid Biopsy Outlook: Product
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 4.3.3.1. Instruments
    • 4.3.3.2. Kits and Reagents
    • 4.3.3.3. Software and Services
  • 4.3.4. Market Attractiveness Analysis: Product
• 4.4. Global Lung Cancer Liquid Biopsy Outlook: Technology
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn), By Technology, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 4.4.3.1. Multi-gene-parallel Analysis (NGS)
    • 4.4.3.2. Single Gene Analysis (PCR Microarrays)
  • 4.4.4. Market Attractiveness Analysis: Technology
• 4.5. Global Lung Cancer Liquid Biopsy Outlook: Biomarker
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn), By Biomarker, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 4.5.3.1. Cell-free DNA (cfDNA)
    • 4.5.3.2. Circulating tumor DNA (ctDNA)
    • 4.5.3.3. Extracellular Vesicles (EVs)
    • 4.5.3.4. Circulating Tumor Cells (CTC)
    • 4.5.3.5. Others
  • 4.5.4. Market Attractiveness Analysis: Biomarker
• 4.6. Global Lung Cancer Liquid Biopsy Outlook: Indication
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
  • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 4.6.3.1. Small Cell Lung Cancer (SCLC)
    • 4.6.3.2. Non-Small Cell Lung Cancer (NSCLC)
  • 4.6.4. Market Attractiveness Analysis: Indication
• 4.7. Global Lung Cancer Liquid Biopsy Outlook: Sample
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Mn), By Sample, 2019-2024
  • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 4.7.3.1. Blood
    • 4.7.3.2. Cerebrospinal Fluid (CSF)
    • 4.7.3.3. Plasma
    • 4.7.3.4. Serum
    • 4.7.3.5. Others
  • 4.7.4. Market Attractiveness Analysis: Sample
• 4.8. Global Lung Cancer Liquid Biopsy Outlook: End User
  • 4.8.1. Introduction / Key Findings
  • 4.8.2. Historical Market Size (US$ Mn), By End User, 2019-2024
  • 4.8.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.8.3.1. Hospitals
    • 4.8.3.2. Reference Laboratories
    • 4.8.3.3. Academic & Research Institutes
    • 4.8.3.4. Others
  • 4.8.4. Market Attractiveness Analysis: End User

5. Global Lung Cancer Liquid Biopsy Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Lung Cancer Liquid Biopsy Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Product
  • 6.2.3. By Technology
  • 6.2.4. By Biomarker
  • 6.2.5. By Indication
  • 6.2.6. By Sample
  • 6.2.7. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 6.4.1. Instruments
  • 6.4.2. Kits and Reagents
  • 6.4.3. Software and Services
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 6.5.1. Multi-gene-parallel Analysis (NGS)
  • 6.5.2. Single Gene Analysis (PCR Microarrays)
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 6.6.1. Cell-free DNA (cfDNA)
  • 6.6.2. Circulating tumor DNA (ctDNA)
  • 6.6.3. Extracellular Vesicles (EVs)
  • 6.6.4. Circulating Tumor Cells (CTC)
  • 6.6.5. Others
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 6.7.1. Small Cell Lung Cancer (SCLC)
  • 6.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 6.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 6.8.1. Blood
  • 6.8.2. Cerebrospinal Fluid (CSF)
  • 6.8.3. Plasma
  • 6.8.4. Serum
  • 6.8.5. Others
• 6.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.9.1. Hospitals
  • 6.9.2. Reference Laboratories
  • 6.9.3. Academic & Research Institutes
  • 6.9.4. Others
• 6.10. Market Attractiveness Analysis

7. Europe Lung Cancer Liquid Biopsy Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product
  • 7.2.3. By Technology
  • 7.2.4. By Biomarker
  • 7.2.5. By Indication
  • 7.2.6. By Sample
  • 7.2.7. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 7.4.1. Instruments
  • 7.4.2. Kits and Reagents
  • 7.4.3. Software and Services
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 7.5.1. Multi-gene-parallel Analysis (NGS)
  • 7.5.2. Single Gene Analysis (PCR Microarrays)
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 7.6.1. Cell-free DNA (cfDNA)
  • 7.6.2. Circulating tumor DNA (ctDNA)
  • 7.6.3. Extracellular Vesicles (EVs)
  • 7.6.4. Circulating Tumor Cells (CTC)
  • 7.6.5. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 7.7.1. Small Cell Lung Cancer (SCLC)
  • 7.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 7.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 7.8.1. Blood
  • 7.8.2. Cerebrospinal Fluid (CSF)
  • 7.8.3. Plasma
  • 7.8.4. Serum
  • 7.8.5. Others
• 7.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.9.1. Hospitals
  • 7.9.2. Reference Laboratories
  • 7.9.3. Academic & Research Institutes
  • 7.9.4. Others
• 7.10. Market Attractiveness Analysis

8. East Asia Lung Cancer Liquid Biopsy Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product
  • 8.2.3. By Technology
  • 8.2.4. By Biomarker
  • 8.2.5. By Indication
  • 8.2.6. By Sample
  • 8.2.7. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 8.4.1. Instruments
  • 8.4.2. Kits and Reagents
  • 8.4.3. Software and Services
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 8.5.1. Multi-gene-parallel Analysis (NGS)
  • 8.5.2. Single Gene Analysis (PCR Microarrays)
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 8.6.1. Cell-free DNA (cfDNA)
  • 8.6.2. Circulating tumor DNA (ctDNA)
  • 8.6.3. Extracellular Vesicles (EVs)
  • 8.6.4. Circulating Tumor Cells (CTC)
  • 8.6.5. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 8.7.1. Small Cell Lung Cancer (SCLC)
  • 8.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 8.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 8.8.1. Blood
  • 8.8.2. Cerebrospinal Fluid (CSF)
  • 8.8.3. Plasma
  • 8.8.4. Serum
  • 8.8.5. Others
• 8.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.9.1. Hospitals
  • 8.9.2. Reference Laboratories
  • 8.9.3. Academic & Research Institutes
  • 8.9.4. Others
• 8.10. Market Attractiveness Analysis

9. South Asia & Oceania Lung Cancer Liquid Biopsy Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product
  • 9.2.3. By Technology
  • 9.2.4. By Biomarker
  • 9.2.5. By Indication
  • 9.2.6. By Sample
  • 9.2.7. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 9.4.1. Instruments
  • 9.4.2. Kits and Reagents
  • 9.4.3. Software and Services
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 9.5.1. Multi-gene-parallel Analysis (NGS)
  • 9.5.2. Single Gene Analysis (PCR Microarrays)
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 9.6.1. Cell-free DNA (cfDNA)
  • 9.6.2. Circulating tumor DNA (ctDNA)
  • 9.6.3. Extracellular Vesicles (EVs)
  • 9.6.4. Circulating Tumor Cells (CTC)
  • 9.6.5. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 9.7.1. Small Cell Lung Cancer (SCLC)
  • 9.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 9.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 9.8.1. Blood
  • 9.8.2. Cerebrospinal Fluid (CSF)
  • 9.8.3. Plasma
  • 9.8.4. Serum
  • 9.8.5. Others
• 9.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.9.1. Hospitals
  • 9.9.2. Reference Laboratories
  • 9.9.3. Academic & Research Institutes
  • 9.9.4. Others
• 9.10. Market Attractiveness Analysis

10. Latin America Lung Cancer Liquid Biopsy Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product
  • 10.2.3. By Technology
  • 10.2.4. By Biomarker
  • 10.2.5. By Indication
  • 10.2.6. By Sample
  • 10.2.7. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 10.4.1. Instruments
  • 10.4.2. Kits and Reagents
  • 10.4.3. Software and Services
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 10.5.1. Multi-gene-parallel Analysis (NGS)
  • 10.5.2. Single Gene Analysis (PCR Microarrays)
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 10.6.1. Cell-free DNA (cfDNA)
  • 10.6.2. Circulating tumor DNA (ctDNA)
  • 10.6.3. Extracellular Vesicles (EVs)
  • 10.6.4. Circulating Tumor Cells (CTC)
  • 10.6.5. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 10.7.1. Small Cell Lung Cancer (SCLC)
  • 10.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 10.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 10.8.1. Blood
  • 10.8.2. Cerebrospinal Fluid (CSF)
  • 10.8.3. Plasma
  • 10.8.4. Serum
  • 10.8.5. Others
• 10.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.9.1. Hospitals
  • 10.9.2. Reference Laboratories
  • 10.9.3. Academic & Research Institutes
  • 10.9.4. Others
• 10.10. Market Attractiveness Analysis

11. Middle East & Africa Lung Cancer Liquid Biopsy Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product
  • 11.2.3. By Technology
  • 11.2.4. By Biomarker
  • 11.2.5. By Indication
  • 11.2.6. By Sample
  • 11.2.7. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 11.4.1. Instruments
  • 11.4.2. Kits and Reagents
  • 11.4.3. Software and Services
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 11.5.1. Multi-gene-parallel Analysis (NGS)
  • 11.5.2. Single Gene Analysis (PCR Microarrays)
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 11.6.1. Cell-free DNA (cfDNA)
  • 11.6.2. Circulating tumor DNA (ctDNA)
  • 11.6.3. Extracellular Vesicles (EVs)
  • 11.6.4. Circulating Tumor Cells (CTC)
  • 11.6.5. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 11.7.1. Small Cell Lung Cancer (SCLC)
  • 11.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 11.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 11.8.1. Blood
  • 11.8.2. Cerebrospinal Fluid (CSF)
  • 11.8.3. Plasma
  • 11.8.4. Serum
  • 11.8.5. Others
• 11.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.9.1. Hospitals
  • 11.9.2. Reference Laboratories
  • 11.9.3. Academic & Research Institutes
  • 11.9.4. Others
• 11.10. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Bio-Rad Laboratories, Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Agilent Technologies, Inc.
  • 12.3.3. Oncocyte Corporation
  • 12.3.4. NeoGenomics Laboratories
  • 12.3.5. Lepu Medical Technology(Beijing)Co.,Ltd
  • 12.3.6. QIAGEN
  • 12.3.7. Thermo Fisher Scientific Inc.
  • 12.3.8. Illumina, Inc.
  • 12.3.9. F. Hoffmann-La Roche Ltd
  • 12.3.10. Sysmex Corporation
  • 12.3.11. BioView
  • 12.3.12. Guardant Health, Inc
  • 12.3.13. SOPHiA GENETICS
  • 12.3.14. BioMark Diagnostics
  • 12.3.15. DELFI Diagnostics, Inc.
  • 12.3.16. Freenome Holdings, Inc.
  • 12.3.17. Foresight Diagnostics, Inc.
  • 12.3.18. Foundation Medicine, Inc.
  • 12.3.19. Pillar Biosciences, Inc.
  • 12.3.20. Caris Life Sciences

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations